and glucagon-receptor activity may influence energy expenditure and liver-related metabolism
Protocols, doses, and reactions reported below come from published clinical trials
Retatrutide is an investigational triple agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
And everyone in the study had diabetes, so no one was taking these medications solely for weight loss
How GLP-1s Affect Appetite When You Have Type 2 Diabetes GLP-1 medications work similarly in people who are taking them for type 2 diabetes as they do in people taking them for weight loss, although the research is still ongoing, says Jennifer Nasser, PhD, RD, an associate professor of nutrition sciences at Drexel University in Philadelphia and spokesperson for the Obesity Society
Track patterns to identify your personal triggers